vs
Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Community Healthcare Trust Inc is the larger business by last-quarter revenue ($31.5M vs $23.0M, roughly 1.4× Intellia Therapeutics, Inc.). Community Healthcare Trust Inc runs the higher net margin — 8.1% vs -416.2%, a 424.2% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 4.8%). Over the past eight quarters, Community Healthcare Trust Inc's revenue compounded faster (7.0% CAGR vs -10.8%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CHCT vs NTLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.5M | $23.0M |
| Net Profit | $2.5M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | 8.1% | -416.2% |
| Revenue YoY | 4.8% | 78.8% |
| Net Profit YoY | 60.2% | 25.7% |
| EPS (diluted) | — | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $31.5M | — | ||
| Q4 25 | $30.9M | $23.0M | ||
| Q3 25 | $31.1M | $13.8M | ||
| Q2 25 | $29.1M | $14.2M | ||
| Q1 25 | $30.1M | $16.6M | ||
| Q4 24 | $29.3M | $12.9M | ||
| Q3 24 | $29.6M | $9.1M | ||
| Q2 24 | $27.5M | $7.0M |
| Q1 26 | $2.5M | — | ||
| Q4 25 | $14.4M | $-95.8M | ||
| Q3 25 | $1.6M | $-101.3M | ||
| Q2 25 | $-12.6M | $-101.3M | ||
| Q1 25 | $1.6M | $-114.3M | ||
| Q4 24 | $1.8M | $-128.9M | ||
| Q3 24 | $1.7M | $-135.7M | ||
| Q2 24 | $-10.4M | $-147.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -428.9% | ||
| Q3 25 | — | -808.9% | ||
| Q2 25 | — | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | — | -1589.0% | ||
| Q2 24 | — | -1998.6% |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 46.6% | -416.2% | ||
| Q3 25 | 5.3% | -735.2% | ||
| Q2 25 | -43.2% | -710.8% | ||
| Q1 25 | 5.3% | -687.6% | ||
| Q4 24 | 6.3% | -1001.2% | ||
| Q3 24 | 5.9% | -1489.5% | ||
| Q2 24 | -37.9% | -2112.6% |
| Q1 26 | — | — | ||
| Q4 25 | $0.52 | $-0.81 | ||
| Q3 25 | $0.03 | $-0.92 | ||
| Q2 25 | $-0.50 | $-0.98 | ||
| Q1 25 | $0.03 | $-1.10 | ||
| Q4 24 | $0.04 | $-1.27 | ||
| Q3 24 | $0.04 | $-1.34 | ||
| Q2 24 | $-0.42 | $-1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $421.3M | $671.4M |
| Total Assets | $1.0B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.6M | — | ||
| Q4 25 | $3.3M | $449.9M | ||
| Q3 25 | $3.4M | $511.0M | ||
| Q2 25 | $4.9M | $459.7M | ||
| Q1 25 | $2.3M | $503.7M | ||
| Q4 24 | $4.4M | $601.5M | ||
| Q3 24 | $2.8M | $658.1M | ||
| Q2 24 | $734.0K | $691.1M |
| Q1 26 | — | — | ||
| Q4 25 | $532.2M | — | ||
| Q3 25 | $530.1M | — | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | — | ||
| Q3 24 | $473.7M | — | ||
| Q2 24 | $457.6M | — |
| Q1 26 | $421.3M | — | ||
| Q4 25 | $429.4M | $671.4M | ||
| Q3 25 | $426.8M | $748.4M | ||
| Q2 25 | $437.8M | $715.3M | ||
| Q1 25 | $461.3M | $779.9M | ||
| Q4 24 | $476.0M | $872.0M | ||
| Q3 24 | $477.2M | $962.6M | ||
| Q2 24 | $497.8M | $971.1M |
| Q1 26 | $1.0B | — | ||
| Q4 25 | $990.8M | $842.1M | ||
| Q3 25 | $987.3M | $925.3M | ||
| Q2 25 | $966.3M | $898.9M | ||
| Q1 25 | $985.1M | $986.2M | ||
| Q4 24 | $992.6M | $1.2B | ||
| Q3 24 | $981.8M | $1.2B | ||
| Q2 24 | $983.2M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.99× | — | ||
| Q2 24 | 0.92× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $56.4M | $-69.3M | ||
| Q3 25 | $12.7M | $-76.9M | ||
| Q2 25 | $13.8M | $-99.6M | ||
| Q1 25 | $14.4M | $-148.9M | ||
| Q4 24 | $58.9M | $-85.2M | ||
| Q3 24 | $13.8M | $-84.8M | ||
| Q2 24 | $16.7M | $-58.2M |
| Q1 26 | — | — | ||
| Q4 25 | $35.9M | $-69.4M | ||
| Q3 25 | $7.6M | $-76.9M | ||
| Q2 25 | $9.6M | $-99.9M | ||
| Q1 25 | $9.7M | $-149.7M | ||
| Q4 24 | $34.2M | $-86.2M | ||
| Q3 24 | $6.7M | $-86.1M | ||
| Q2 24 | $9.5M | $-59.2M |
| Q1 26 | — | — | ||
| Q4 25 | 116.0% | -301.6% | ||
| Q3 25 | 24.6% | -558.2% | ||
| Q2 25 | 32.9% | -701.0% | ||
| Q1 25 | 32.3% | -900.1% | ||
| Q4 24 | 116.9% | -669.4% | ||
| Q3 24 | 22.5% | -945.2% | ||
| Q2 24 | 34.7% | -850.9% |
| Q1 26 | — | — | ||
| Q4 25 | 66.3% | 0.5% | ||
| Q3 25 | 16.3% | 0.2% | ||
| Q2 25 | 14.5% | 1.7% | ||
| Q1 25 | 15.6% | 4.4% | ||
| Q4 24 | 84.1% | 7.6% | ||
| Q3 24 | 24.2% | 14.0% | ||
| Q2 24 | 26.1% | 14.5% |
| Q1 26 | — | — | ||
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHCT
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
